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Abstract
Background: Photoplethysmography with a digital sensor (ClearSight, Edwards Lifesciences, Irvine, CA, USA)
connected to a dedicated monitor (EV 1000, Edwards Lifesciences) was recently proposed for use in performing
hemodynamic optimization during surgery. The objective of this study is to evaluate the effect of
photoplethysmography on the incidence of postoperative complications compared with the conventional
hemodynamic algorithm, which uses mean arterial pressure.
Methods/design: The hemodynamic optimization using photoplethysmography (PANEX3) trial is a monocentric,
randomized, single-blind, controlled, two parallel arm, superiority trial, randomizing 160 patients with an
intermediate risk of postoperative complications after colorectal surgery. Informed consent will be obtained from all
participants. The hemodynamic optimization is conducted using a specified hemodynamic algorithm either with
photoplethysmography (the photoplethysmography group) or with conventional mean arterial pressure (the
control group). The anesthesiologist performed a 1:1 randomization the day before surgery using a scratch card,
which is available 24/7. The randomization sequence is generated using permutated blocks. Both the patients and
surgeons are blinded to the allocation group. The primary outcome is the incidence of at least one postoperative
complication during the 30 days following surgery. Two independent experts, who were blinded to the group
allocations, validate the complication for each patient using an a priori classification. The secondary outcomes are
to study the total number of postoperative complications, the real length of hospital stays, and the postoperative
mortality between each group.
Discussion: The PANEX3 trial is the first randomized controlled study conducted to investigate whether
perioperative hemodynamic optimization using photoplethysmography during colorectal surgery could decrease
the incidence of patients having at least one postoperative complication.
Trial Registration: ClinicalTrials.gov Identifier: NCT02343601
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Background
Although more than 320 million surgeries are performed
worldwide each year [1], recent data show that the peri-
operative morbidity and mortality remain significant [2].
The concept of perioperative hemodynamic optimization
is important to decrease the morbidity and length of the
hospital stay after noncardiac surgery [3]. Currently, ex-
pert guidelines recommend a maximization of stroke
volume using titrated fluid loading with cardiac output
monitoring [4, 5]. However, although such a strategy has
been shown to be beneficial for patients, it is rarely used
at the bedside [6, 7]. The invasiveness of cardiac output
monitoring, lack of knowledge, and time constraints
could partially explain these disappointing results [8].
Noninvasive and plug-and-play cardiac output monitor-
ing could increase the adherence to the guidelines. Using
a simple finger sensor, the plethysmography displays
continuous blood pressure and beat-to-beat cardiac
output measurements. Previous studies reported en-
couraging results with this technology during the
perioperative period [8–11]. However, no phase III study
has been conducted to assess the clinical utility of photo-
plethysmography to decrease the perioperative morbidity
[12], and a benefit remains to be established.
The PANEX3 study aims to compare in patients with
an intermediate risk of postoperative complications after
colorectal surgery the effects of photoplethysmography
using a perioperative hemodynamic optimization algo-
rithm with a conventional hemodynamic algorithm that
uses mean arterial pressure.
Methods/design
Ethics and study design
The perioperative hemodynamic optimization using
photoplethysmography in colorectal surgery (PANEX3)
study is a randomized, controlled, two-arm trial. The insti-
tutional review board (IRB) of the University Hospital of
Caen (Comité de Protection des Personnes Nord-Ouest
III, Avenue la Côte de Nacre, Niveau 03, Porte 03–508, 14
033 Caen Cedex 9, France) approved the study (Registra-
tion number ID RDB: 2014-A00870-47 on 3 December
2014). The PANEX3 study is being conducted in accord-
ance with the Declaration of Helsinki and was registered
on 13 June 2014 on the ClinicalTrials.gov website with the
trial identification number NCT02343601. The PANEX3
trial follows the CONSORT statement [13], and the CON-
SORT diagram is given in Fig. 1. All patients are asked for
written informed consent, as required by the IRB, in ac-
cordance with the Declaration of Helsinki; informed con-
sent will be obtained from all participants.
Study population
All patients for planned colorectal surgeries are eligible
for the study.
Patients fulfilling one or more of the following criteria
will not be included: lack of informed consent prior to
randomization, use of another hemodynamic monitor
for cardiac output measurement, chronic kidney disease
with creatinine clearance < 30 ml/min, black skin (limit
of photoplethysmography technology), pregnant patients,
age < 18 years, or under legal protection. This provides
good technical conditions for the photoplethysmography
and a relatively homogenous study population for the in-
terpretation of the results.
The included patients are at moderate surgical risk,
based on the surgical procedure and/or the medical
history for each patient. Patients with high surgical risk
according to the medical history will have a cardiac out-
put monitor [4, 5], and they will be not included in the
study.
Randomization
Randomization is performed by the anesthesiologist the
day before surgery using a scratch card available 24/7 in
the hospital. The randomization sequence is generated
using permutated blocks.
Interventions
On arrival in the operating room, each patient re-
ceives the usual monitoring, including a lead ECG,
noninvasive blood pressure, pulse oximetry, and a
photoplethysmography monitor using a digital sensor
(ClearSight, Edwards Lifesciences) connected to a dedi-
cated monitor (EV 1000, Edwards Lifesciences). Included
patients are assigned to the control group (blinded moni-
tor) or the photoplethysmography group (monitor avail-
able to guide anesthesia), according to the randomization.
After the heart reference system is zeroed at the mid-
axillary line, the monitoring is continuously recorded from
the start of general anesthesia induction until discharge
from the recovery room. All photoplethysmography data
is then recovered by an independent investigator not in-
volved in the patient care.
In the control group (Fig. 2), the hemodynamic goal is a
mean arterial pressure (MAP) > 65 mmHg; if the MAP is
under this value, the clinician can prescribe an intravenous
fluid challenge using 3 ml/kg of gelatin over 10 minutes,
renewable once, and then a vasopressor thereafter (ephe-
drine until 30 mg, and norepinephrine thereafter).
In the photoplethysmography group (Fig. 3), the
hemodynamic target includes the stroke volume and
the MAP: the fluid challenge prescription depends on
the changes in stroke volume, according to recent
guidelines [4], whereas the vasopressor use depends on a
MAP < 65 mmHg after the maximization of the stroke
volume.
The allocated therapy is delivered until discharge from
the recovery room.
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Standard procedures
The anesthesia medications follow the local protocol for
the induction (propofol, sufentanil, and atracurium) and
the maintenance of anesthesia (sevoflurane, sufentanil,
and atracurium). The postoperative pain management
follows another local protocol using intravenous (IV)
lidocaine (1.5 mg/kg intravenous drip (IVD) at the start
of anesthesia, then 2 mg/kg/h in a syringe driver during
surgery, and 1.5 mg/kg/h during recovery room), para-
cetamol (1 g x 4 per day), nefopam (80 to 100 mg in syr-
inge driver per day), and oxycodone (5 mg up to 4 per
day if pain evaluation > 3/10). For all patients, surgeons
Fig. 2 Hemodynamic algorithm for the control group. *Norepinephrine after the failure of the use of ephedrine, which is defined by the use of
30 mg of ephedrine without the desired hemodynamic response. Norepinephrine: dosage began at 0.05 μg/kg/min and then was adjusted in
steps of 0.05 μg/kg/min. MAP, mean arterial pressure
Fig. 1 Consort diagram of the PANEX3 trial
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perform scar infiltration with 20 ml of ropivacaine
0.75 %. The concomitant use of regional anesthesia
(transverse abdominal plane block with 20 ml of ropiva-
caine 0.75 %, and/or spinal anesthesia using morphine
150 to 400 μg) is left to the discretion to the attending
anesthesiologist.
The antibiotic prophylaxis and enhanced recovery
after the elective colorectal surgery program follow the
recent guidelines [14].
The ventilator settings include a tidal volume using
6 to 8 ml/ideal body weight, a positive end-
expiratory pressure between 5 and 8 cm H2O, lung
recruitment maneuvers (30 cm H2O during 30 sec-
onds every 30–45 minutes), a respiratory rate and an
FiO2 according to a range of end-tidal carbon diox-
ide tension between 35 and 45 mm Hg, and a pulse
oximetry > 96 %.
Study endpoints
The primary outcome is the incidence of at least
one postoperative complication during the 30 days
following surgery. Two independent experts confirm
the presence of the complication using an a priori
classification (Table 1) in accordance with recent
guidelines [15]. These experts are not involved in
the study and work in a different university
hospital.
The secondary outcomes are the total number of post-
operative complications, the real length of hospital stays,
and the postoperative mortality.
Blinding
A coding list has been generated using the SAS software
package V.9.4. During surgery and postoperative care,
both surgeons and patients are blinded to the allocated
group. The material used in the photoplethysmography
group and in the control group is similar, in keeping with
the blinded design. Therefore, patients in each group re-
main indistinguishable. Only the anesthesiology staff and
the research staff can view the monitor (blinded in the
control group) and know the group allocation. The sur-
geons are the postoperative care providers, who will de-
cide the length of hospital stay while staying totally
blinded to the group allocation. The two independent ex-
perts are also blinded to the group allocation.
Intention-to-treat analysis
Patients with a serious undesirable event during the sur-
gery, which justifies invasive hemodynamic monitoring
(arterial catheter or cardiac output monitoring), or with-
out photoplethysmography signal will not be treated
using the study group algorithm allocation. They will
then receive different monitoring or treatment at the
discretion of the attending anesthesiologist but will be
analyzed according to their initial assigned group follow-
ing the intention-to-treat principle.
Sample size estimation
Based on previous published studies [16, 17], two groups
of 80 patients are needed to detect a decrease in the in-
cidence from 40 % to 20 % of patients suffering at least
Fig. 3 Hemodynamic algorithm for the photoplethysmography group. *Norepinephrine after the failure of the use of ephedrine, which is defined
by the use of 30 mg of ephedrine without the desired hemodynamic response. Norepinephrine: dosage began at 0.05 μg/kg/min and then was
adjusted in steps of 0.05 μg/kg/min. MAP, mean arterial pressure
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Table 1 A priori definition of postoperative complications
Complication Definition
Paralytic ileus Failure to tolerate solid food or defecate for 3 or more days after surgery
Infection, source uncertain Strong clinical suspicion of infection, but the source has not been confirmed because clinical information
suggests more than one possible site, meeting two or more of the following criteria: core temperature
< 36 °C or > 38 °C, white cell count > 12 x 109/l or < 4 x 109/l, respiratory rate > 20 breath/minute or
PaCO2 < 4.7 kPa, pulse rate > 90/min.
Surgical site infection (superficial) Infection occurs within 30 days after surgery and involves only skin and subcutaneous tissue of the incision
and (purulent drainage from superficial incision, organisms isolated from superficial surgical site, or diagnosis
of incisional surgical site infection by a surgeon or attending physician, or clinical symptoms in this surgical
superficial site.
Surgical site infection (deep) Infection occurs within 30 days after surgery and involves deep soft tissues and purulent drainage, or
abscess or other evidence of infection during surgery or radiological examination, or a deep incision
spontaneously dehisces or is deliberately opened by a surgeon and its culture is positive or the patient
is symptomatic.
Surgical site infection (organ/space) Infection that involves any part of the body, excluding the fascia or muscle layers, and meets the criteria
further indicated. Infection occurs within 30 days after surgery, and the infection appears to be related to
the surgical procedure and involves any part of the body, excluding the skin incision, fascia or muscle layers
opened or manipulated during the operative procedure, and the patient has at least one of the following
criteria: purulent drainage from a drain that is placed through a stab wound into the organ/space;
or organisms isolated from an aseptically obtained culture of fluid or tissue in the organ/space; or
an abscess or other evidence of infection involving the organ/space that is found on direct examination,
during reoperation, or by histopathological or radiological examination; or diagnosis of an organ/space
surgical site infection by a surgeon or attending physician).
Laboratory-confirmed bloodstream
infection
Patient has a recognized pathogen cultured from one or more blood cultures, and the organism cultured
from the blood is not related to an infection at another site, or the patient had clinical signs (fever > 38 °C,
hypotension, or chills) and at least one of the following common skin contaminants cultured from two or
more blood cultures drawn on separate occasions, or one blood culture from a patient with an intravascular
line, and the physician institutes appropriate antimicrobial therapy, or positive blood antigen test.
Anastomotic breakdown Leak of luminal contents from a surgical connection between two hollow viscera. The luminal contents may
emerge either through the wound or at the drain site, or they may collect near the anastomosis, causing
fever, abscess, septicemia, metabolic disturbance, and/or multiple organ failure.
Postoperative hemorrhage Blood loss within 72 h after surgery, which requires a transfusion of blood
Gastrointestinal bleed Gastrointestinal bleed is defined as unambiguous clinical or endoscopic evidence of blood in the
gastrointestinal tract. Upper gastrointestinal bleeding (or hemorrhage) is that originating proximal to
the ligament of Treitz, in practice from the esophagus, stomach, and duodenum. Lower gastrointestinal bleeding
is that originating from the small bowel or colon.
Urinary tract infection Positive urine culture of ≥105 colony forming units/ml with no more than two species of microorganisms,
and with at least one sign (among fever > 38 °C, dysuria, suprapubic tenderness, costovertebral angle pain, or
tenderness with no other recognized cause.
Acute kidney injury 1.5 times baseline value within 7 days.
Respiratory failure Postoperative PaO2 < 8 kPa (60 mm Hg) on room air, a PaO2:FI02 ratio < 40 kPa (300 mmHg) or arterial
oxyhemoglobin saturation measured with pulse oximetry < 90 % and requiring oxygen therapy.
Pneumonia New or progressive and persistent infiltrates or consolidation or cavitation in at least one chest radiograph,
with at least one (among fever > 38 °C, white cell count > 12 x 109/l or < 4 x 109/l, altered mental status with
no other recognized cause for adults > 70 years old), and at least two (among new onset or change in
character in sputum, new onset or worsening cough or dyspnea or tachypnea, rales breath sounds, or
worsening gas exchange).
Pulmonary embolism Pulmonary embolism confirmed by cardiothoracic angiography in the postoperative period.
Acute respiratory distress syndrome New worsening respiratory symptoms, bilateral opacities in chest imaging, without cardiac failure, and
PaO2/FiO2 < 300 mm Hg.
Cardiogenic pulmonary edema Evidence of fluid accumulation in the alveoli due to poor cardiac function.
Myocardial infarction Increase in troponin Ic, with at least one value above the 99th percentile (≥0.04 ng/ml) upper reference limit,
and at least one the following criteria: ST or T wave ECG changes or new left bundle branch block, development
of pathological Q waves on ECG, echocardiographic evidence of new loss of viable myocardium or new regional
wall motion abnormality, or identification of an intracoronary thrombus at angiography.
Myocardial injury Peak troponin Ic ≥ 0.04 ng/ml (99th percentile).
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one postoperative complication, using a two-sided α-risk
at 0.05 and a β-risk at 0.20. Because the incidence of
complications is uncertain, checking the number of pa-
tients having at least one postoperative complication in
the control group will be conducted after 80 patients
have been included to verify the power of the study.
However, no interim analysis is planned. We anticipate
no missing data for the primary outcome (incidence of
at least one postoperative complication). For the per-
protocol analysis (sensitivity analysis), the handling of
missing data (surgery cancelled, failure of photoplethys-
mography monitoring, or serious undesirable event
during the surgery) will be anticipated, with five supple-
mental patients being included for each group. Never-
theless, all randomized patients will be analyzed in the
allocated group for the main intention-to-treat analysis.
In addition, to comply with the intent-to-treat analysis,
missing data for the primary outcome will handled by
multiple imputations (PROC MI in SAS) and analyzed
in sensitivity analyses using PROC MIANALYZE in SAS
V9.4 (SAS institute, Cary, NC, USA).
Statistical plan
Categorical variables will be described as percentages, and
continuous variables will be described as mean (Standard
Deviation) or median (interquartile range), as appropriate.
The analysis for the primary outcome will follow the
intent-to-treat principle in which all the randomized pa-
tients will be analyzed in the assigned group. The principal
comparison will be performed by the Fisher exact or the
Pearson chi-square test for heterogeneity for the rate of
postoperative complications, including the group as inde-
pendent variables. All statistical analysis will be conducted
with SAS V9.4 (SAS institute, Cary, NC). A p < 0.05 will
denote statistical significance.
Registration
Data will be collected and registered using electronic
case report forms (eCRFs) by a dedicated local research
technician. A research coordinator will centralize and
verify the data.
Data collected and registered
Baseline characteristics and pre-randomization data will
be collected: sex, age, height, weight, ideal body weight,
Lee score [18], smoking status, history and type of dia-
betes mellitus, dyslipidemia, history of cardiovascular
disease (systemic hypertension, ischemic heart disease,
valvular heart disease, peripheral vascular disease, or car-
diac medications), history of respiratory disease (asthma
with chronic treatment, chronic obstructive pulmonary
disease requiring corticosteroid daily or oxygen at home
or history of hospitalization for decompensation or non-
invasive ventilation), history of hepatic disease (Child
Pugh classification of cirrhosis [19]), renal insufficiency
(classified according to the glomerular filtration rate
[20]), history of neoplasia, and baseline bloods (creatin-
ine, bilirubin, albumin, and rate of prothrombin).
During the anesthesia and surgical procedures, the fol-
lowing will be recorded: the type of procedure (first or
reoperation), surgical site (right, left, or total colectomy,
protectomy, or coloprotectomy), duration of anesthesia
and surgery, blood loss and transfusion requirements, all
drugs used during anesthesia (anesthetics, opiates, and
neuromuscular blocking agents), all administered fluids
(number of titrated fluid loadings, and total fluid load-
ing), and all vasoactive drugs.
Data from the EV 1000 monitor will be extracted
(mean MAP, mean stroke volume, mean stroke volume
variation, mean heart rate, mean MAP/Heart rate ratio,
and proportion (%) of time during MAP < 65 mm Hg
and < 55 mm Hg). The clinical tolerance of the sensor
will be evaluated with a numerical pain scale, and a skin
examination (paresthesia, erythema, and necrosis).
During postoperative days 1, 3, and 5, blood sam-
ples will be sent for the following analyses: creatinine,
troponin Ic, leukocyte, and hemoglobin. If the core
temperature > 38 °C, a blood culture, urine culture, and
drain fluid culture (if available) will be performed.
From postoperative day 0 until 30 days following sur-
gery, the postoperative complications will be recorded
(Table 1).
The real hospital length of stay and the survival status
at day 30 following the inclusion will be recorded.
Record keeping
Consent forms and eCRFs will be retained for 15 years
at the University Hospital of Caen in accordance with
the French law.
Study organization
The study promotion is performed by the University
Hospital of Caen, France. Industry does not provide fi-
nancial support; nor is it involved in the study protocol.
Table 1 A priori definition of postoperative complications (Continued)
Arrhythmia Evidence of cardiac rhythm disturbance in electrocardiograph.
Cardiac arrest Cessation of cardiac mechanical activity, as confirmed by the absence of signs of circulation.
Stroke Embolic, thrombotic, or hemorrhagic cerebral event, with persistent residual motor, sensory, or cognitive
dysfunction.
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Duration and timeline
Patients from the French University Hospitals of Caen
can be included during a 2-year period beginning in
December 2014.
Protocol, approval from the ethical committee, finan-
cial support, the eCRF, and the interactive web response
system (IWRS) were developed in 2014. Inclusions of
patients were planned to take place during 2015 and
2016. The database should be closed during 2016 and
will be followed by data analysis, manuscript writing,
and submission for publication.
Discussion
The photoplethysmography is a plug-and-play
hemodynamic monitoring device, which could allow
hemodynamic optimization during the perioperative
period for a wide patient population, including pa-
tients at moderate surgical risk. The PANEX3 trial is
the first randomized controlled study powered to in-
vestigate the photoplethysmography as a noninvasive
hemodynamic tool in patients scheduled for colorectal
surgery compared with the conventional hemodynamic al-
gorithm using mean arterial pressure.
The primary endpoint of the trial is the incidence of at
least one postoperative complication. Two independent
experts validate the presence of the complication using
an a priori classification in accordance with recent
guidelines [15]. These experts are not involved in the
study and do not work at the same university hospital.
They are also blinded to the group allocation. These
procedures reinforce the internal validity of the present
study. The objective to show a decrease of 50 % in the
main goal could be challenging, but this result is in
accordance with previous reports [16, 17] and can be
considered clinically relevant. If the photoplethysmogra-
phy algorithm is easy, safe, and effective to use, then this
technology could be integrated to the concept of
perioperative surgical home [21]. Moreover, another
study was designed alongside the PANEX3 trial, and
it is investigating the medico-economic aspect of
photoplethysmography.
The present study propose a hemodynamic algorithm
with photoplethysmography using both stroke volume
maximization and continuous mean arterial pressure
monitoring compared with a control algorithm using
only intermittent mean arterial pressure measurements.
Recently, a large retrospective study has described the
possible relation between value and duration of arterial
hypotension during anesthesia and poor clinical outcome
[22]. An algorithm with continuous monitoring of arterial
pressure could decrease the duration of hypotension in
comparison with conventional intermittent arterial pres-
sure measurement [23], but no outcome study is available
with a hemodynamic algorithm using continuous arterial
pressure monitoring. The PANEX3 study, which uses a
complete and continuous hemodynamic algorithm (mean
arterial pressure and stroke volume), is designed to evalu-
ate this strategy.
The limitations of the study require some comment.
First, the study population was restricted to colorectal
surgery in patients with an intermediate surgical risk.
However, the length of surgery and postsurgical recovery
time can be long, explaining a possible key role of
hemodynamic optimization during this period. Further
studies could be developed in other type of surgeries
with intermediate surgical risk. Second, the study popu-
lation was not selected as high-risk surgery because the
photoplethysmography hemodynamic monitoring is con-
sidered of benefit for the intermediate surgical risk
population [4]. However, this population of patients is
the more frequently encountered population in practice.
Inclusion criteria were large for the study population, re-
inforcing the external validity of the study.
In conclusion, PANEX3 is a controlled randomized
trial powered to test the hypothesis that perioperative
hemodynamic optimization using photoplethysmography
could decrease the incidence of at least one postopera-
tive complication. The PANEX3 trial also evaluates the
impact of a hemodynamic algorithm using photoplethys-
mography on the total number of postoperative compli-
cations, the real length of the hospital stay, and the
postoperative mortality.
Trial status
The trial is ongoing and actively enrolling.
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